<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74056">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02150343</url>
  </required_header>
  <id_info>
    <org_study_id>TH005</org_study_id>
    <nct_id>NCT02150343</nct_id>
  </id_info>
  <brief_title>Phase II HDM-SPIRE Safety and Efficacy Study</brief_title>
  <official_title>A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Circassia Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <authority>Germany: Paul-Ehrlich-Institut</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the treatment effect of three treatment regimens of
      HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue
      medication usage, Quality of Life and Sleep Quality
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Combined score of symptoms and allergy medication</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of subject allergy symptoms (e.g. sneezing, watery eyes) and use of allergy medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>up to 52 weeks after randomisation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and frequency of Adverse Events</measure>
    <time_frame>up to 52 weeks after randomisations</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">660</enrollment>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>HMD-SPIRE Treatment 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 x 12 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDM-SPIRE Treatment 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 x 12 nmol HDM-SPIRE 4 weeks apart followed by a second course of 4 x 12 nmol HDM-SPIRE 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDM-SPIRE Treatment 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 x 20 nmol HDM-SPIRE followed by 4 x placebo 4 weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>8 x placebo 4 weeks apart</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM-SPIRE</intervention_name>
    <description>1 dose every 4 weeks</description>
    <arm_group_label>HMD-SPIRE Treatment 1</arm_group_label>
    <arm_group_label>HDM-SPIRE Treatment 2</arm_group_label>
    <arm_group_label>HDM-SPIRE Treatment 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 dose every 4 weeks</description>
    <arm_group_label>HMD-SPIRE Treatment 1</arm_group_label>
    <arm_group_label>HDM-SPIRE Treatment 3</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, aged 18-65 years.

          -  Moderate to severe rhinoconjunctivitis on exposure to HDM for at least 1 years.

          -  Mean TRSS ≥10

          -  Positive skin prick test to Der p and Der f.

          -  Dep p and Der f specific IgE ≥0.7 kU/L

        Exclusion Criteria:

          -  Diagnosis of asthma requiringGlobal Initiative for Asthma (GINA) Step 3
             (www.ginasthma.org)or higher treatment

          -  FEV1 &lt;80% of predicted.

          -  Clinically significant confounding symptoms of allergy to seasonal allergens during
             the final evaluation period.

          -  Significant symptoms of another clinically relevant illness that is likely to affect
             scoring of rhinoconjunctivitis symptoms.

          -  Clinically relevant abnormalities detected on physical examination.

          -  History of severe drug allergy, severe angioedema or anaphylactic reaction to food.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>May 27, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cat allergy</keyword>
  <keyword>Rhinoconjunctivitis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
